Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients

Jacek Grabowski, Rolf Richter, Hannah Rittmeister, Radoslav Chekerov, Hannah Woopen, Jalid Sehouli

Anticancer Research · 2018 · 18 citations · 0 references

Open access

Abstract

Fewer chemotherapy cycles and preterm discontinuation were more frequent in patients with lower BMI. Hematological toxicity and higher medication intake appeared more often in patients with higher BMI.